Lead Product(s) : Buloxibutid
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vicore Reports Positive Results from Phase 2a AIR Trial of Buloxibutid in IPF
Details : C21 (buloxibutid) is an angiotensin II type 2 receptor agonist, which is currently being evaluated for the treatment of patients with idiopathic pulmonary fibrosis.
Brand Name : C21
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 20, 2024
Lead Product(s) : Buloxibutid
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Buloxibutid
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vicore Initiates Clinical Proof-Of-Concept Study of Endothelial Dysfunction
Details : C21 is an angiotensin II type 2 receptor agonist, which s being developed for the treatment endothelial dysfunction (reflecting blood vessel health) in patients with type-2-diabetes-mellitus.
Brand Name : C21
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 03, 2023
Lead Product(s) : Buloxibutid
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Buloxibutid
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vicore's Digital Therapeutic For IPF Patients Shows Nearly 50% Anxiety Reduction In Pilot Study
Details : C21 is a small molecule compound, which is in clinical development for the treatment of IPF and COVID-19. The experimental programme will assess the potential of C21 for addressing fibrosis, inflammation and vasculopathy in a variety of diseases such as ...
Brand Name : C21
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 06, 2022
Lead Product(s) : Buloxibutid
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The results show restoration of lung function in COVID-19 on top of corticosteroids and remdesivir with the company's oral drug C21, suggesting that C21 can become an important complement to vaccines to combat the COVID-19 pandemic.
Brand Name : VP01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 01, 2021
Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Vicore Pharma has submitted a Letter of Intent to file a clinical trial application to the UK regulatory agency for a phase II study with its proprietary compound C21 in patients with COVID-19.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 31, 2020
Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?